Printer Friendly

GILLE JOINS MGI PHARMA AS VICE PRESIDENT, GENERAL COUNSEL

 GILLE JOINS MGI PHARMA AS VICE PRESIDENT, GENERAL COUNSEL
 MINNEAPOLIS, Jan. 14 /PRNewswire/ -- MGI Pharma, Inc. (NASDAQ: MOGN) announced today that Lori-Jean Gille, J.D. Magna Cum Laude has joined the company as vice president, general counsel. Gille will be responsible for managing all legal affairs of the company.
 Gille has joined the company from Dorsey & Whitney, a Minneapolis law firm, where she was director of Dorsey & Whitney's General Counsel Program, which provides on-site legal counsel to companies without in- house legal staffs. MGI Pharma had been a client of Gille through this program since 1990. Prior to Dorsey & Whitney, Gille had been general counsel and secretary of United HealthCare Corporation.
 MGI Pharma, Inc., acquires, develops and markets pharmaceuticals prescribed and recommended by physician specialists. The company currently sells DIDRONEL(R) I.V. Infusion and Oratect(TM) Gel and has a number of products in various stages of development.
 -0- 1/14/92
 /CONTACT: Lori Weiman of MGI Pharma, 612-939-4666/
 (MOGN) CO: MGI Pharma, Inc. ST: Minnesota IN: MTC SU: PER


KH -- MN017 -- 9791 01/14/92 18:16 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 14, 1992
Words:180
Previous Article:WEST GROTON MAN PLEADS GUILTY TO MAIL FRAUD IN CONNECTION WITH APPLICATION FOR DISABILITY BENEFITS FROM THE FEDERAL GOVERNMENT
Next Article:HARN RESIGNS AS PRESIDENT, CHIEF OPERATING OFFICER AT R.G. BARRY
Topics:


Related Articles
MGI PHARMA ACQUIRES NEW CRITICAL CARE DRUG; MGI 330 COULD IMPROVE DIAGNOSIS OF HEART DISEASE AND RECOVERY FROM ISCHEMIA
MGI PHARMA EXPANDS BOARD
MGI PHARMA, INC. APPOINTS NEW VICE PRESIDENT OF SALES AND MARKETING; COMMENTS ON SECOND QUARTER GROWTH
MGI PHARMA, INC. ANNOUNCES SECOND QUARTER RESULTS
MGI PHARMA, INC., ANNOUNCES APPROVAL OF SALAGEN TABLETS IN FRANCE, IRELAND AND GREECE
CHARLES N. BLITZER APPOINTED PRESIDENT AND CEO OF MGI PHARMA, INC.
STUDY ON MGI PHARMA SALAGEN TABLETS PRESENTED AT THE INTERNATIONAL SYMPOSIUM ON SUPPORTIVE CARE IN CANCER
MGI PHARMA Announces Management Promotions and Elects New Board Member

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters